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Abstract: 
Cytochromes P450 (CYPs) are a super family of heme-containing enzymes well-known for their monooxgenase reaction. There are 
57 CYP isoenzymes found in human which exhibit specific physiological functions. Thirteen members of this super family are 
classified as "orphan" CYP because of their unknown enzymatic functions. CYP4V2 is found to be a potential drug target for Bietti 
crystalline corneoretinal dystrophy (BCD). However, three-dimensional structure, the active site topology and substrate binding 
modes of CYP4V2 remain unclear. In this study, the three-dimensional model of CYP4V2 was constructed using the homology 
modeling method. Four possible fatty acid substrates namely, caprylic, lauric, myrisitc and palmitic acids were optimized and 
evaluated for drug likeness using Lipinski’s rule of five. Further, these substrates were docked into active sites of CYP4V2 and 
several key residues responsible for substrate binding were identified. These findings will be helpful for the structure-based drug 
design and detailed characterization of the biological roles of CYP4V2. 
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Background: 
Cytochrome P450s (CYPs) are important heme-containing 
proteins, well-known for their monooxgenase reaction. They are 
involved in the metabolism of xenobiotics and endogenous 
compounds, such as steroids and fatty acids. Human CYPs are 
primarily membrane-associated proteins located either in the 
inner membrane of mitochondria or in the endoplasmic 
reticulum of cells. Some CYPs metabolize only one (or a very 
few) substrate, while others may metabolize multiple 
substrates. Cytochrome P450 enzymes are present in most 
tissues of the human body, and play an important role in 
hormone synthesis and breakdown, cholesterol synthesis, and 
vitamin D metabolism. Cytochrome P450 enzymes also function 
to metabolize potentially toxic compounds, including drugs 
and products of endogenous metabolism [1]. In human there 
are fifty-seven functional cytochrome P450 isoenzymes with 
well-established role in the metabolism of endogenous sterols, 
bile acids, vitamins and fatty acids. However, thirteen human 
P450s still remain "orphans" because their functional roles have 
yet to be elucidated [2]. H u m a n  C Y P 4  f a m i l y  c o n s i s t s  o f  6  
subfamilies, 12 genes and 10 pseudo genes. Human CYP4V2, a 
relatively new member of human cytochrome P450 enzymes is 
termed as an orphan P450 because its substrate specificity and 
physiological roles are unknown. The CYP450 protein family is 
a group of enzymes that use iron to oxidise various substrates, 
including potentially harmful substances, thereby making them 
more water soluble and promoting their biological processing.  
 
CYP4V2 gene encoded as a member of the cytochrome P450 
hemethiolate protein super family is involved in oxidizing 
various substrates in the metabolic pathway. The gene contains 
11 exons spanning 21.7 kb and is expressed in various tissues, BIOINFORMATION  open access 
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most abundantly in the retina. Mutations in CYP4V2 gene result 
in Bietti crystalline corneoretinal dystrophy (BCD) [3] which is 
an autosomal recessive retinal dystrophy. The symptoms of 
BCD include crystals in the cornea, yellow shiny deposits on the 
retina, progressive atrophy of the retina, choriocapillaries and 
c h o r o i d  ( t h e  b a c k  l a y e r s  o f  t h e  e y e ) .  B C D  i s  a  r a r e  d i s e a s e  
leading to progressive night blindness and visual field 
constriction. BCD appears to be more common in people with 
Asian ancestry [4, 5]. The issue of CYP4V2 substrate specificity 
is important because an intriguing genetic association has 
emerged between CYP4V2 and BCD. It is proposed that the 
protein encoded by CYP4V2 plays a role in processing lipids 
such as fatty acids or steroid metabolism in the eye. Wilson and 
associates  [6] found crystals resembling cholesterol or 
cholesterol esters in the retina, and complex lipid inclusions in 
the cornea, conjunctiva, fibroblasts and circulating 
lymphocytes, suggesting that BCD may be a systemic 
abnormality of lipid metabolism. CYP4V2 is widely distributed 
in the eye and can selectively omega-hydroxylase saturated 
medium-chain fatty acids. The defective omega-oxidation of 
ocular fatty acids/lipids secondary to mutations in the CYP4V2 
gene appears to be a plausible mechanism underlying BCD. The 
amino acidic sequence of orphan human protein CYP4V2 is 
available but to date its crystal structure has not been resolved. 
Experimental functional studies of CYP4V2 suggest that 
saturated fatty acids like caprylic, lauric, myrisitc and palmitic 
acids can act as possible substrates [7].  
 
Structural information might help us to understand the ligand 
interaction and channeling of CYP4V2. Structural studies 
relying on computational comparative modeling and molecular 
docking have been used to gain insight into finding active site 
topology, identifying key ligand-interacting residues and 
interaction energy of substrates. In this study, 3D structure of 
CYP4V2 was constructed by using comparative modeling and 
the model was refined by energy minimization. After structural 
evaluation, the reliable model of CYP4V2 was docked into 
possible fatty acid substrates to explore substrate specificity. 
 
 
Figure 1: Multiple sequence alignment of target (CYP4V2: 
Q6ZWL3) and six templates (3EBS, 1PO5, 1NR6, 3E4E, 3CZH 
and 1TQN) using ClustalW program. The red colour indicates 
conserved residue and yellow colour indicates a semi-
conserved substitution. 
 
Figure 2: (a) Ramachandran plot of CYP4V2 (b) Prosa z score of 
CYP4V2. 
 
Methodology: 
Homology modeling of human CYP4V2 
The sequence of human CYP4V2 was obtained from the 
UniprotKB database (accession no: Q6ZWL3). For template 
selection, the sequence was submitted to PSI-BLAST against 
Protein Data Bank (PDB). The templates 1TQN, 3CZH, 3E4E, 
1NR6, 1PO5 and 3EBS having high similarity were selected and 
further submitted to ClustalW [8] for template target alignment. 
The coordinates for heme were obtained from 1TQN and 
positioned as in the template. The Modeller 9v2 program [9] 
was employed to generate the 3D model of CYP4V2. The model 
which ranked first based on the internal scoring function of 
Modeller was selected and subjected to energy minimization 
using YASARA software [10]. The optimized model was 
subjected to quality assessment with respect to its geometry and 
energy aspects. Graphical presentations of the 3D model were 
prepared using Pymol. 
 
 
Figure 3: (a) Homology model of CYP4V2 (b) Superimposed 
structure of CYP4V2 with 1TQN (c) Substrate recognition sites 
of CYP4V2: SRS-1: red, SRS-2: green, SRS-3: blue, SRS-4: yellow, 
SRS-5: magenta and SRS-6: orange (d) Predicted active site of 
CYP4V2. BIOINFORMATION  open access 
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Figure 4: 2D structure of ligands; (a) Caprylic acid (b) lauric 
acid (c) Myristic acid (d) Palmitic acid. 
 
Prediction of binding site in homology model of CYP4V2 
The homology model of CYP4V2 was submitted to ConSurf 
Server [11] for identification of functional regions by detecting 
the structurally conserved binding regions among their close 
sequence homologues. 
 
Ligand optimization and evaluation of drug likeness 
The possible substrates like caprylic, lauric, myristic and 
palmitic acids were downloaded from the Pubchem in Structure 
Data Format (SDF). Conversion of SDF to Protein Data Bank 
(PDB) format was carried out using Open Babel program [12]. 
The MMFF94 force field was used for energy minimization of 
ligand molecules. Gasteiger partial charges were added to the 
ligand atoms, non-polar hydrogen atoms were merged and 
rotatable bonds were defined. Ligand geometries and electric 
properties were calculated using MOPAC2009. Further, ligands 
were evaluated for drug likeness using Lipinski’s rule of five 
[13]. According to this rule, an ideal drug molecule should have 
a molecular weight of less than 500, total number of hydrogen 
bonds should not exceed 5, logP value should be less than 5 and 
the sum of N and O should not be more than 10. Further poor 
absorption or permeation is more likely when a ligand molecule 
violates this rule. 
 
 
Figure 5: Close up View of CYP4V2 with (a) Caprylic acid (b) 
lauric acid (c) Myristic acid (d) Palmitic acid. Key residues are 
labeled. Substrates are shown in green stick. 
 
Molecular docking 
Docking calculations were carried out using Docking Server 
[14] to compute the free energy of binding on protein model. 
Essential hydrogen atoms, Kollman united atom type charges 
and solvation parameters were added with the aid of AutoDock 
tools [15]. Affinity (grid) maps of 60X60X60Å grid points and 
0.375 Å spacing were generated using the Autogrid program. 
AutoDock parameter set and distance dependent dielectric 
functions were used in the calculation of the Van der Waals and 
the electrostatic terms respectively. Docking simulations were 
performed using the Lamarckian genetic algorithm (LGA) and 
the Solis and Wets local search method. Initial position, 
orientation and torsions of the ligand molecules were set 
randomly and all rotatable torsions were released during 
docking. Each docking experiment was derived from 10 
different runs that were set to terminate after a maximum of 
250000 energy evaluations. The population size was set to 150. 
During the search, a translational step of 0.2 Å and quaternion 
and torsion steps of 5 were applied. 
 
Results and Discussion: 
The protein sequence of human CYP4V2 was queried against 
the Protein Data Bank (PDB) using PSI-BLAST and the result 
showed less than 30% identity between target and the 
templates. The top six templates (1TQN, 3CZH, 3E4E, 1NR6, 
1PO5 and 3EBS) were selected and their sequences were 
multiple aligned with CYP4V2 sequence. The majority of the 
structures were found to be conserved except for few gap 
inserts. The sequence conservation and the signature motifs of 
CYP4V2 were examined using multiple sequence alignment 
with templates (Figure 1). The structural motifs were in the I 
helix (xGxxT), a tetra peptide in the K helix (ExxR), a dodeca 
peptide prior to the L helix (ZxxPxxZxPxxZ) and a deca peptide 
between L helix and the dodeca peptide (FxxGxxxCxG), where, 
Z could be any aromatic amino acid and x could be any residue. 
Among these signature motifs, FxxGxxxCxG is the 
characteristic motif for the CYP super family, which includes a 
conserved cystine residue that ligates to the Fe of the heme. 
Several signature motifs were conserved for CYP4V2 as per 
pervious findings [16, 17]. The conservation of sequence 
indicates that CYP4V2 model construction based on this 
alignment is reliable. The templates structures did not contain 
residues in N-terminal membrane-binding domain and thus the 
first 36 residues at the N-terminal were not included in model 
construction.  The resulting alignment was used as input for 
Modeller to generate the initial 3D model of CYP4V2. The 
model of CYP4V2 was subjected to energy minimization using 
YAMBER force field implemented in YASARA. The total 
energy was 25283762.4 and -264806.2 kJ/mol for homology 
model of CYP4V2 before and after minimization. The energy 
minimized model was subjected to several structural quality 
assessment methods. The Procheck [18] evaluation showed that 
98.5% of residues were in the allowed region and 1.5% in the 
disallowed region (Figure 2a). Prosa [19] evaluation showed Z 
score of -6.81 (Figure 2b) indicating that the predicted CYP4V2 
model was a reliable one. The model contained several 
structurally conserved regions quite similar as those of other 
P450s such as helices D, E, I, J, K and L and the heme group 
sandwiched between helices (Figure 3a). Comparison of the 
model with the templates by superposition clearly showed that 
the overall CYP fold was preserved in CYP4V2 (Figure 3b). BIOINFORMATION  open access 
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Based on Gothoh’s proposal, predicted substrate binding sites 
(SRS) of the CYP4V2 such as SRS-1, SRS-2, SRS-3, SRS-4, SRS-5 
and SRS-6 were observed respectively in B helix, F helix, G 
helix, I helix, K helix and between β4 and β5 (Figure 3c).The 
final model was deposited in Protein Model Database (PMDB) 
[20] and it is available under ID: PM0077758. The CYP4V2 
model was further tested to predict functional regions using 
ConSurf server (Figure 3d) by identifying high conservational 
score (Table 1, see supplementary material).  The optimized 
and energy minimized substrates namely caprylic (Figure 4a), 
lauric  (Figure 4b), myrisitc (Figure 4c) and palmitic acids 
(Figure 4d) were subjected to ligand geometry and calculation 
of electric properties (Table 2, see supplementary material).  
Further, the ligand was also evaluated for drug ability 
assessment using Lipinski’s rule of five. It was observed from 
the calculated ligand properties that all the substrates did not 
violate this rule. 
 
To determine the key residues responsible for substrates 
interaction, the homology model of CYP4V2 was docked with 
selected fatty acid substrates. The calculated binding energies of 
CYP4V2 with lauric acid, myristic acid and palmitic acid were 
respectively   -5.99, -5.72 and -6.14 kcal/mol. The lowest energy 
was found with caprylic acid as -4.30 kcal/mol (Table 3, see 
supplementary material). The negative and low value of free 
energy of binding indicates a strong favorable bond between 
CYP4V2 and the caprylic acid in most favorable conformations. 
Docking of CYP4V2 with caprylic acid revealed that major 
residues involved were Phe398, Leu136 and Phe329 which 
formed hydrophobic interaction, while Ser394 formed polar 
interaction (Figure 5a). With lauric acid, major residue Leu136 
formed hydrophobic interaction while Phe398 formed both 
hydrophobic and cation interaction (Figure 5b). With myristic 
acid, the binding residues Ile 506 and Phe328 formed 
hydrophobic interaction, and Asp332 formed polar interaction 
(Figure 5c). With palmitic acid, Phe398 formed hydrophobic 
interaction (Figure 5d). Major residues involved in interaction 
with all selected fatty acid substrates were Phe328, Phe398, 
Leu136 and Ile506 (Table 4, see supplementary material). 
 
Conclusion: 
The orphan human protein CYP4V2 was suggested to be 
associated with Bietti crystalline corneoretinal dystrophy (BCD) 
and a role in fatty acid and steroid metabolism in the eye. It was 
suggested to be potential drug target for BCD, but lack of 
structural information hinders the detailed characterization of 
its biological roles and it application in the structure based 
design. For this reason, the homology model of CYP4V2 was 
constructed using comparative modeling and assessed for 
geometric and energy aspects. To provide useful information 
and characterize the CYP4V2 function, four possible saturated 
fatty acid substrates such as caprylic, lauric, myrisitc and 
palmitic acids were docked into active site of CYP4V2 to 
explore favourable binding modes and their substrate 
specificity. The interaction energy calculated between CYP4V2 
and substrates revealed that caprylic acid had a lowest energy 
followed by myristic, lauric and palmitic acids. Several key 
residues Phe328, Phe398, Leu136 and Ile506 had predominant 
contribution to the substrate binding with CYP4V2. The key 
residues identified through ConSurf analysis (functional region 
identification) and docking studies were in concurrence with 
each other reflecting the importance of crucial residues 
involved in substrate binding. The key residues identified from 
the present study could be potential candidates for site directed 
mutagenesis studies. Furthermore, these residues might play a 
role in ligand-channeling and for identifying the reaction center 
of the protein. The structural information obtained from this 
study will also be useful for the structure-based drug design of 
CYP4V2. 
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Supplementary material: 
Table 1: Function regions of CYP4V2 predicted using ConSurf server with high amino acid conservation score (9 - conserved, 1 - 
variable). 
Residue  Conservation score  Buried (B)/Exposed (E)  Residual variety 
W130 9  B  W,G 
L131 9  B  M,I,L 
G132 9  E  S,A,N,R,K,G 
L133 5  E  A,F,S,T,N,K,E,Q,C,D,R,I,L 
G134 9  B  S,C,G 
L135 9  E  M,P,I,L 
L136 8  B  F,M,I,L,V 
T137 8  E  T,N,R,I,L,V 
S138 9  E  F,A,S,T,N,C,D,G,L 
L150 8  B  A,F,M,I,L 
T151 9  E  A,W,T,D,N,I,G 
P152 9  E  S,Q,M,P 
T153 8  E  S,A,T,C 
F154 9  B  F,L 
H155 9  B  H,N,P 
F156 9  B  H,S,F,L,Y 
R320 9  E  Q,C,I,K,R,L 
E321 9  E  A,Q,N,D,K,E 
E322 9  E  Q,EV 
V323 9  B  I,V 
D324 9  E  H,N,D,E 
T325 9  B  T,I,LF 
F326 9  B  F,I,V 
M327 9  B  T,M,I,L,V 
F328 9  B  F,I,L 
E329 8  E  A,R,G,E 
G330 9  B  A,G,BV 
H331 9  E  H,Q,N 
D332 9  E  D,E 
T333 9  E  S,T 
F398 5  B  F,T,Y,V,H,Q,M,I,L 
I506 8  B  T,I,L,V 
L507 8  B  T,N,V,H,M,I,R,L 
R508 8  E  S,M,T,I,K,R,L 
 
Table 2: Ligand properties 
Ligand Molar 
weight 
LogP  H acceptor  H donor  pKa  pKb  psa  logD  logK  Total charge
  
Caprylic  acid 143.204  2.44  2  1  5.19 0  37.30  0.63 1.417  0.001 
Lauric  acid  200.318  3.21  2  2  11.88  4.03 40.46  3.21 -5.2 0.002 
Myristic  acid 227.363  4.82  2  1  4.95 0  37.30  2.78 -8.031  0.001 
Palmitic acid  255.416  5.61  2  1  4.95 0  37.30  3.57 -13.55  0.001 
 
Table 3: Docking analysis of CYP4V2 with selected ligands 
Ligand Free  Energy  of 
Binding 
(kcal/mol) 
Inhibition Constant, 
Ki 
(uM) 
vdW + Hbond + 
desolv Energy 
(kcal/mol) 
Electrostatic Energy 
(kcal/mol) 
Total 
Intermolec. 
Energy 
(kcal/mol) 
Interact. 
Surface 
Caprylic acid  -4.30   707.14   -5.85   -0.05   -5.89   353.002 
Lauric acid  -5.99   40.85   -7.64   -0.05   -7.69   427.342 
Myristic acid  -5.72   64.20   -8.70   0.07   -8.63   480.982 
Palmitic acid  -6.14   31.58   -9.60   -0.03   -9.63   534.563 
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Table 4: Details of intermolecular interactions in the binding site of CYP4V2 with ligands 
Ligand complex  Hydrophobic*  Polar  Cation   Other 
Caprylic acid  C2-LEU136  (3.25),  
C1-LEU136 (3.13), 
C7-PHE328 (3.62),   
C6-PHE398  (3.76)  
  
O2 -SER394  
(3.38) 
- C1-GLU329(3.51),   
C3-GLU329(3.58), 
C3-THR333(3.63) 
C5-THR333(3.38) 
C7-THR333(3.33) 
C8-SER394(3.89) 
O1-SER394 (3.61) 
O2-SER394(3.48) 
O2-PHE398(3.43) 
Lauric acid  C10-LEU136 (3.87) 
C11-ILE230 (3.51) 
C11-PHE231(3.87) 
C5-PHE328(3.68) 
C7-PHE328(3.84) 
C9-PHE328(3.48) 
C11-PHE328(3.77) 
C6-PHE398(3.59) 
C8-PHE398(3.82) 
C7-ILE506(3.69) 
C9-ILE506(3.89) 
C11-ILE506(3.50) 
 
- H1-PHE328(3.35)  O1-LEU136(3.52) 
C9-SER227(3.36) 
C11-SER227(3.78) 
H1-GLU329(3.67) 
O2-GLU329(3.53) 
H2-GLU329(3.53) 
C7-ASP332(3.86) 
C9-ASP332(3.10) 
O2-THR333(3.31) 
H2-THR333(3.36) 
C4-SER394(3.76) 
Myristic Acid  C6-LEU136(3.53) 
C13-ILE230(3.84) 
C10-PHE328 
C12-PHE329(3.71) 
C14-PHE328(3.62) 
C2-PHE398(3.78) 
C1-PHW398(3.65) 
C3-PHE398(3.69) 
C9-PHE398(3.51) 
C11-LEU505(3.40) 
C13-LEU505(3.71) 
C7-ILE506(3.76) 
C14-ILE506(3.90) 
 
O2-ASP332(3.14) -  O1-PHE328(3.42) 
C14-ASP332(3.90) 
C8-THR333(3.64) 
C10-THR333(3.87) 
O2-THR333(3.71) 
C3-SER394(3.32) 
C5-SER394(3.26) 
O2-ILE506(3.80) 
O1-ILE506(3.77) 
Palmitic acid  C2-LEU136 (3.11) 
C1-LEU136 (3.61) 
C4-LEU136 (3.64) 
C12-ILE230 (3.80) 
C15-PRO393 (3.37) 
C5-PHE398 (3.45) 
C2-PHE398 (3.20) 
C4-PHE398 (3.76) 
C6-PHE398 (3.30) 
C8-PHE398 (3.88) 
C10-PHE398 (3.14) 
C12-LEU505(3.14) 
C14-LEU505(3.17) 
- - C11-THR333(3.33) 
C13-THR333(3.84) 
C15-THR(3.63) 
C7-SER394(3.36) 
C9-SER394(3.32) 
C13-SER394(3.32) 
C15-SER394(3.58) 
O2-PHE398(3.84) 
*C(X) –R(X) (D): 
C(X) - atom name, R(X) - residue name, number within 4 Angstrom from the given ligand atom, (D) - lowest inter atomic distance between the given 
ligand atom and the residue. For example: C2-LEU136 (3.11), here C2 is C(X), LEU136 is R(X) and 3.11 is (D) 